1. Home
  2. NDLS vs CING Comparison

NDLS vs CING Comparison

Compare NDLS & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Noodles & Company

NDLS

Noodles & Company

N/A

Current Price

$15.24

Market Cap

68.7M

ML Signal

N/A

CING

Cingulate Inc.

HOLD

Current Price

$5.64

Market Cap

59.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NDLS
CING
Founded
1995
2012
Country
United States
United States
Employees
N/A
14
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
68.7M
59.3M
IPO Year
2013
N/A

Fundamental Metrics

Financial Performance
Metric
NDLS
CING
Price
$15.24
$5.64
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
N/A
$34.50
AVG Volume (30 Days)
29.8K
532.6K
Earning Date
05-06-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$495,089,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.37
N/A
52 Week Low
$0.47
$3.16
52 Week High
$15.98
$11.89

Technical Indicators

Market Signals
Indicator
NDLS
CING
Relative Strength Index (RSI) 66.55 63.97
Support Level $0.59 $5.58
Resistance Level N/A $6.67
Average True Range (ATR) 0.85 0.36
MACD 0.09 0.10
Stochastic Oscillator 86.02 100.00

Price Performance

Historical Comparison
NDLS
CING

About NDLS Noodles & Company

Noodles & Co is a restaurant concept offering lunch and dinner within the fast-casual segment of the restaurant industry. The company's menu includes a variety of cooked-to-order dishes, including noodles and pasta, soups, salads and appetizers. The company also provides dining, pick-up and delivery services. It is focused on offering customers flavorful, cooked-to-order dishes in a warm and welcoming environment at an attractive value. It has approximately 340 company-owned restaurants and 83 franchise restaurants in 31 states.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: